Sequencing Strategies to Guide Decision Making in Cancer Treatment

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57–70. 10647931

2. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004 Aug;10(8):789–99. doi: 10.1038/nm1087 15286780

3. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014 Jan 23;505(7484):495–501. doi: 10.1038/nature12912 24390350

4. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010 Oct;11(10):685–96. doi: 10.1038/nrg2841 20847746

5. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960–6. doi: 10.1200/JCO.2006.07.9525 17452677

6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med. 2005 Oct 20;353(16):1673–84. doi: 10.1056/NEJMoa052122 16236738

7. Hortobagyi GN. Opportunities and challenges in the development of targeted therapies. Semin Oncol. 2004 Feb;31(1 Suppl 3):21–7.

8. Sidorova JY, Saltykova LB, Lyschov AA, Zaritskey AY, Abdulkadyrov KM, Blinov MN. A rapid RT-PCR based method for the detection of BCR-ABL translocation. Mol Pathol. 1997 Oct;50(5):266–8. 9497918

9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–82. 3798106

10. Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician. 2010 Jun 1;81(11):1339–46. 20521754

11. Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst. 1961 Nov;27:1013–35. 14480645

12. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, et al. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4504–8. 8183938

13. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999 Dec;107(3):587–99. 10583264

14. Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin Y-L, Borger DR, et al. A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer. J Mol Diagn. 2011 Jan;13(1):74–84. doi: 10.1016/j.jmoldx.2010.11.010 21227397

15. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine: Tumour genotyping for personalized cancer care. EMBO Mol Med. 2010 May;2(5):146–58. doi: 10.1002/emmm.201000070 20432502

16. Mullard A. NCI-MATCH trial pushes cancer umbrella trial paradigm. Nat Rev Drug Discov. 2015 Aug;14(8):513–5. doi: 10.1038/nrd4694 26228747

17. New genetic tests become standard of cancer care in BC. BC Cancer Agency. http://www.bccancer.bc.ca/about/news-stories/news/2016/new-genetic-tests-become-standard-of-cancer-care-in-bc. September 7, 2016.

18. Hyman DM, Solit DB, Arcila ME, Cheng DT, Sabbatini P, Baselga J, et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today. 2015 Dec;20(12):1422–8. doi: 10.1016/j.drudis.2015.08.005 26320725

19. Do K, O’Sullivan Coyne G, Chen AP. An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Chin Clin Oncol. 2015 Sep;4(3):31. doi: 10.3978/j.issn.2304-3865.2015.08.01 26408298

20. Kim E. ASCO’s TAPUR Study: Off-Label Drugs for Actionable Mutations. Medscape. http://www.medscape.com/viewarticle/862427. April 29, 2016.

21. Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer. 2014 Jul 1;111(1):17–24. doi: 10.1038/bjc.2014.211 24762958

22. Le Tourneau C, Delord J-P, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015 Oct;16(13):1324–34. doi: 10.1016/S1470-2045(15)00188-6 26342236

23. Jones SJ, Laskin J, Li YY, Griffith OL, An J, Bilenky M, et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 2010;11(8):R82. doi: 10.1186/gb-2010-11-8-r82 20696054

24. Laskin J, Jones S, Aparicio S, Chia S, Ch’ng C, Deyell R, et al. Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000570. doi: 10.1101/mcs.a000570 27148575

25. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014 Feb 2;46(3):225–33. doi: 10.1038/ng.2891 24487277

26. Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, et al. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol. 2014 Jul;12(7):e1001906 doi: 10.1371/journal.pbio.1001906 25003521